期刊文献+

2型糖尿病肾病患者尿肝型脂肪酸结合蛋白水平的临床意义 被引量:1

Clinical significance of urinary liver-type fatty binding protein levels in type2 diabetic nephropathy
下载PDF
导出
摘要 目的探讨检测尿肝型脂肪酸结合蛋白(L-FABP)水平对2型糖尿病肾病的临床意义。方法根据24 h尿蛋白排泄率(UAER)将89例2型糖尿病肾病患者分成三组:单纯2型糖尿病组(Ⅰ组)30例(UAER<30 mg/24 h)、早期2型糖尿病肾病组(Ⅱ组)29例(UAER 30~300 mg/24 h)和临床2型糖尿病肾病组(Ⅲ组)30例(UAER>300 mg/24 h)。并选择30例体检者作对照组(NC组),采用酶联免疫吸附试验(ELISA)法测定其尿L-FABP水平,并检测血肌酐(Scr)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白-胆固醇(LDL-C)、高密度脂蛋白-胆固醇(HDL-C)等指标,及估测肾小球滤过率估算值(eGFR),同时分析尿L-FABP与脂蛋白的相关性。结果Ⅰ组、Ⅱ组和Ⅲ组的尿L-FABP和UAER(24 h)水平均明显高于NC组,差异均有统计学意义(t分别=1.94、2.32、2.77、2.04、2.89、3.41, P均<0.05),Ⅱ组及Ⅲ组尿L-FABP和UAER(24 h)水平均高于Ⅰ组,差异均有统计学意义(t 分别=2.22、3.65、2.88、4.12, P均<0.05);Ⅲ组尿L-FABP和UAER(24 h)水平均高于Ⅱ组,差异均有统计学意义(t分别=3.11、3.48, P均<0.05)。Ⅰ组、Ⅱ组和Ⅲ组的Scr、TC、TG、HDL-C水平均明显高于NC组,eGFR水平均低于NC组,差异均有统计学意义(t分别=2.48、2.89、3.18、2.55、2.92、3.67、2.62、2.78、3.24、2.39、2.68、2.99、2.64、3.58、4.67, P均<0.05)。尿L-FABP水平与Scr和尿白蛋白呈明显性正相关(r=0.39、0.54,P均<0.05),与eGFR呈明显负相关(r=-0.66,P<0.05)。结论尿L-FABP对2型糖尿病肾病有较高的敏感性,提示其是较好的诊断标记物之一。 Objective To investigate the clinical significance of urinary liver-type fatty binding protein(L-FABP) levels of type2 diabetic nephropathy(DN). Methods A total of 89 patients with DN were randomly divided into 3 groups by 24-hour urine protein excretion rate(UAER):pure type2 diabetes group as groupⅠwhose UAER was lower than 30 mg per 24 hours, early type2 diabetic nephropathy group as group Ⅱ whose UAER was between 30 and 300 mg per 24 hours and clinical type2 diabetic nephropathy group as groupⅢwhose UAER was higher than 300 mg per 24 hours. 30 healthy vol-unteers were selected as controls. Urinary L-FABP levels were measured by ELISA and the levels of Scr, TC, TG, LDL-C, HDL-C and GFR estimate were detected. The correlation between urinary L-FABP and lipoprotein was analyzed. Re-sults Urinary L-FABP levels and UAER of DN patients were significantly higher than the control group (t=1.94, 2.32, 2.77, 2.04, 2.89, 3.41,P〈0.05).Urinary L-FABP levels and UAER of group Ⅱ and Ⅲ were significantly higher than group I(t=2.22, 3.65, 2.88, 4.12,P〈0.05). Urinary L-FABP levels and UAER of groupⅢwere significantly higher than group Ⅱ (t=3.11, 3.48,P〈0.05). The levels of Scr, TC, TG, HDL-C in DN patients were significantly higher than the control group, while the eGFR level were significantly lower than the control group(t=2.48, 2.89, 3.18, 2.55, 2.92, 3.67, 2.62, 2.78, 3.24, 2.39, 2.68, 2.99, 2.64, 3.58, 4.67, P〈0.05). Urinary L-FABP was positive related to Scr and uri-nary protein (r=0.39, 0.54, P〈0.05) while was negative related to eGFR (r=-0.66,P〈0.05). Conclusion Urinary L-FABP have high sensitivity to type2 DN. It might be a novel diagnostic marker for DN.
出处 《全科医学临床与教育》 2013年第5期508-510,共3页 Clinical Education of General Practice
关键词 糖尿病肾病 肝型脂肪酸结合蛋白 诊断 diabetic nephropathy liver-typefatty binding protein diagnosis
  • 相关文献

参考文献10

  • 1Bloom CA, Rand JS. Diabetes and the kidney in human and veterinary medicine[J]. Vet Clin North Am Small Anim Pract, 2013, 43(2): 351-365.
  • 2Zuo N, Suzuki Y, Sugaya T, et al. Protective effects of tu- bular liver-type fatty acid-binding protein against glomeru- lar damage in murine IgA nephropathy[J]. Nephrol Dial Transplant,201l, 26(7): 2127-2137.
  • 3McCullough PA, Shaw AD, Haase M, et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth acute dialysis quality initiative consensus conference[J]. Contrib Nephrol, 2013, 182(3): 13-29.
  • 4Pelsers MM. Fatty acid-binding protein as marker for renal injury[J]. Seand J Clin Lab Invest Suppl, 2008, 241(3): 73-77.
  • 5钱荣立.关于糖尿病的新诊断标准与分型[J].中国糖尿病杂志,2000,8(1):5-6. 被引量:2313
  • 6全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估[J].中华肾脏病杂志,2006,22(10):589-595. 被引量:706
  • 7Yokoyama T, Kamijo-Ikemori A, Sugaya T, et al. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage[J]. Am J Pa- thol, 2009, 174(6 ) : 2096-2106.
  • 8Kamijo-Ikemori A, Sugaya T, Ichikawa D, et al. Urinary liver type fatty acid binding protein in diabetic nephropathy[J]. Clin Chim Acta,2013, 42(4) : 104-108.
  • 9Kamijo-Ikemori A, Sugaya T, Yasuda T, et al. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients[J]. Dia- betes Care, 2011, 34( 3 ) : 691-696.
  • 10曾宪飞,李军民,谈昀,王小刚.尿肝型脂肪酸结合蛋白与糖尿病肾损伤的相关性[J].现代检验医学杂志,2013,28(1):56-58. 被引量:7

二级参考文献34

  • 1全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估[J].中华肾脏病杂志,2006,22(10):589-595. 被引量:706
  • 2Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem, 1992,38 : 1933-1953.
  • 3Giovannetti S, Barsotti G. In defense of creatinine clearance.Nephron, 1991,59: 11-14.
  • 4Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med,1999,130:461-470.
  • 5Levey AS, Greene T, Kusek J, et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol, 2000, 11 : A0828 (abstract).
  • 6Eknoyaa G, Levin N. NKF-K/DOQI Clinical Practice Guidelines: Update 2000. Foreword. Am J Kidney Dis,2001, 37 (1 Suppl 1):S5-S6. Erratum in: Am J KidneyDis, 2001,38:917.
  • 7Zuo L, Ma YC, Zhou YH, et al. Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am .I Kidney Dis, 2005, 45:463-472.
  • 8Blaufox MD, Aurell M, Bubeck B, et al. Report of the Radionuclides in Nephrourology Committee on renal clearance.J Nucl Med, 1996, 37:1883-1890.
  • 9Chantler C, Barratt TM. Estimation of glomerular filtration rate from plasma clearance of 51-chromium edetic acid. Arch Dis Child, 1972, 47:613-617.
  • 10Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known.1916. Nutrition, 1989,5 : 303-311.

共引文献3021

同被引文献9

  • 1Thumser AE, Moore JB, Plant NJ. Fatty acid binding pro- teins., tissue-specific functions in heaith and disease[J]. Curt Opin Clin Nutr Metab Care, 2014,17(2) :124-129.
  • 2Kakoti A, Goswami P. Heart type fatty acid binding protein: structure, function and biosensing applications for early de- tection of myocardial infarction [J]. Biosens Bioelectron, 2013,43(12) :400-411.
  • 3Atshaves BP, Martin GG, Hostetler HA, et al. Liver fatty acid-binding protein and obesity [J]. J Nutr Biochem, 2010, 21(113 : 1015-1032.
  • 4Kamiio-Ikemori A, Ichikawa D, Matsui K, et al . Urinary L- type fatty acid binding protein (L-FABP) as a new urinary bi- omarker promulgated by the Ministry of Health, Labour and Welfare in Japan FJ]. Rinsho Byori, 2013,61(7) : 635-640.
  • 5Singh DK, Winocour P, Farrington K. Mechanisms of dis- ease: the hypoxic tubular hypothesis of diabetic nephropathy [J]. Nat Clin Pract Nephrol, 2008,4(2):216-226.
  • 6Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid-binding protein in acute ischemic injury [J]. J Am Soc Nephrol, 2007, 18(25) :2894-2902.
  • 7Nielsen SE, Sugaya T, Hovind P, et al . Urinary liver-type fatty acid-binding protein predicts progressi0n to nephropathy in type 1 diabetic patients [J]. Diabetes Care, 2010,33(16) : 1320-1324.
  • 8孙华,郭玉珊,郑娜.尿肝型脂肪酸结合蛋白与糖尿病肾病的相关性[J].中国老年学杂志,2013,33(23):5814-5815. 被引量:2
  • 9尹德海,郑法雷,段琳,李艳,金晶,孙琦,向红丁.低分子蛋白尿对2型糖尿病肾病病程进展的提示作用[J].中华老年医学杂志,2003,22(11):645-648. 被引量:3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部